Professor Alberto Auricchio, MD is Professor of Medical Genetics at the “Federico II” University in Naples. He has a joint appointment at Telethon Institute of Genetics and Medicine in Naples where he is Full Investigator, Director of the Molecular Therapy Program and AAV Vector Core Supervisor. Prof. Auricchio’s research is focused on gene therapy of retinal and metabolic diseases using adeno-associated viral vectors. Prof. Auricchio is co-author of more than 120 peer-reviewed publications on international scientific journals, and inventor on several international patents on the use of viral vectors for gene therapy.
Prof. Auricchio is a member of the Editorial boards of Human Gene Therapy, Molecular Therapy and EMBO Molecular Medicine. Prof. Auricchio received the 2006 Outstanding New Investigator Award of the American Society of Gene Therapy, and has been nominated in 2007 “Cavaliere of the Italian Republic” by the President of the Italian Republic. Prof. Auricchio has been selected as recipient of both the European Research Council Consolidator and Advanced Grants, in 2011 and 2016, respectively. Prof. Auricchio is coordinator of the EU funded project MeuSIX – “Clinical trial of gene therapy for MPS VI – a severe lysosomal storage disorder” and is currently involved as senior scientist in a long-term strategic collaboration with Shire Pharmaceuticals over 5 years to provide exclusive access to three major research streams which collectively embrace 13 indications.